Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q32 Bio Inc.

2.00
+0.16008.70%
Post-market: 2.000.00000.00%16:05 EDT
Volume:121.08K
Turnover:237.01K
Market Cap:24.40M
PE:-0.30
High:2.01
Open:1.85
Low:1.85
Close:1.84
Loading ...

Q32 Bio Reports 'Encouraging' Alopecia Areata Results as Atopic Dermatitis Study Fails to Meet Primary Endpoint; Shares Sink Premarket

MT Newswires Live
·
11 Dec 2024

Q32 Bio Inc : Piper Sandler Cuts Target Price to $20 From $85

THOMSON REUTERS
·
11 Dec 2024

U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen

Reuters
·
11 Dec 2024

Q32 Bio Shares Drop to New Low After Alopecia Drug Bempikibart Test Results

Dow Jones
·
11 Dec 2024

BUZZ-Q32 Bio plummets as dermatitis drug fails in part of a study

Reuters
·
11 Dec 2024

Q32 Bio reports results from SIGNAL-AA Phase 2a clinical trial

TIPRANKS
·
11 Dec 2024

Q32 Bio : Plans to Expand Signal-Aa Phase 2a Clinical Trial and Enroll Additional Patients Evaluating Bempikibart in Aa

THOMSON REUTERS
·
11 Dec 2024

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

THOMSON REUTERS
·
11 Dec 2024

Q32 Bio : Signal-Ad Phase 2a Clinical Trial in Atopic Dermatitis Demonstrated Promising Findings in Part a but Did Not Meet Primary Endpoint in Part B

THOMSON REUTERS
·
11 Dec 2024

Q32 Bio Inc: Across Both Trials, Bempikibart Was Observed to Be Safe and Well Tolerated

THOMSON REUTERS
·
11 Dec 2024

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%

Simply Wall St.
·
04 Dec 2024

Top Premarket Gainers

MT Newswires Live
·
25 Nov 2024

Q32 Bio Inc expected to post a loss of $1.25 a share - Earnings Preview

Reuters
·
09 Nov 2024

Q32 Bio Q3 2024 GAAP EPS $(1.46) Misses $(1.31) Estimate, Cash And Cash Equivalents Of $89.1M As Of September 30, 2024 Expected To Provide Financial Runway Into Mid-2026

Benzinga
·
07 Nov 2024

Q32 Bio Inc : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $90

THOMSON REUTERS
·
24 Oct 2024

Raymond James Initiates Q32 Bio at Strong Buy With $90 Price Target

MT Newswires Live
·
24 Oct 2024